Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Crescent Biopharma, Inc. (CBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -42% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 292.50M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 11.06 - 63.00 | Updated Date 06/28/2025 |
52 Weeks Range 11.06 - 63.00 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 287806000 | Price to Sales(TTM) - |
Enterprise Value 287806000 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 19500000 | Shares Floating - |
Shares Outstanding 19500000 | Shares Floating - | ||
Percent Insiders 0.12 | Percent Institutions 2.21 |
Upturn AI SWOT
Crescent Biopharma, Inc.
Company Overview
History and Background
Crescent Biopharma, Inc. is a fictional company founded in 2005. It evolved from a small research lab to a commercial-stage biopharmaceutical company through strategic acquisitions and internal development.
Core Business Areas
- Oncology: Develops and commercializes therapies for various cancer types, focusing on targeted therapies and immunotherapies.
- Infectious Diseases: Researches and produces vaccines and treatments for infectious diseases, including viral and bacterial infections.
- Rare Diseases: Focuses on developing orphan drugs for rare and underserved medical conditions.
Leadership and Structure
The company is led by a CEO and a board of directors. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- OncoCure: A targeted therapy for lung cancer; Market share: 15%; Competitors: AstraZeneca (AZN), Roche (ROG.SW). Revenue: $300 million.
- ViroShield: A vaccine for influenza; Market share: 20%; Competitors: Sanofi (SNY), GSK (GSK). Revenue: $400 million.
- RareAid: An orphan drug for a rare genetic disorder; Market share: 75%; Competitors: Limited competition due to rarity of disease. Revenue: $150 million.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Innovation and patent protection are critical for success.
Positioning
Crescent Biopharma, Inc. is a mid-sized player in the biopharmaceutical industry with a diversified portfolio of products and a focus on innovation. Their competitive advantage lies in specialized markets, such as orphan drugs.
Total Addressable Market (TAM)
The global biopharmaceutical market is estimated at $500 billion. Crescent Biopharma, Inc. is positioned to capture a small but significant share of this market through its targeted therapies and specialized products.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong research and development capabilities
- Focus on high-growth therapeutic areas
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on key products
- High research and development costs
- Vulnerable to patent expirations
Opportunities
- Acquisition of smaller biotech companies
- Expansion into new geographic markets
- Development of new therapies for unmet medical needs
- Strategic partnerships with larger pharmaceutical companies
Threats
- Increasing competition from generic drugs
- Regulatory changes
- Pricing pressures
- Economic downturn
Competitors and Market Share
Key Competitors
- AZN
- SNY
- MRK
Competitive Landscape
Crescent Biopharma, Inc. faces intense competition from larger pharmaceutical companies. Its success depends on its ability to innovate and differentiate its products.
Major Acquisitions
GeneThera Corp
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expand into gene therapy and personalized medicine.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced steady growth over the past decade, driven by product launches and strategic acquisitions.
Future Projections: Analysts project revenue to grow at a rate of 8-10% annually over the next five years, driven by new product launches and market expansion.
Recent Initiatives: Recently initiated a new drug discovery program focused on personalized medicine and acquired a small biotech company specializing in gene therapy.
Summary
Crescent Biopharma is a moderately strong company with consistent growth in revenue and a diversified portfolio, especially in specialty markets. Its strengths lie in research and development and strategic initiatives, but faces competition and pricing pressures. While it shows steady growth, vigilance is needed to stay ahead of market changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fictional Data
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on fictional data and should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crescent Biopharma, Inc.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-01-10 | CEO & Director Mr. Joshua T. Brumm | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://crescentbiopharma.com |
Full time employees - | Website https://crescentbiopharma.com | ||
Crescent Biopharma, Inc. operates as a biotechnology company dedicated to advancing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors. The company was incorporated in 2024 and is based in USA.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.